Phase 3Completed
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia
- Sponsor
- Organon and Co (Industry)
- Enrollment
- 2,815 enrolled
- Conditions
- Hypercholesterolemia
- Interventions
- MK0653A, ezetimibe (+) simvastatin; Comparator: Rosuvastatin
- Ages
- adults, older adults
- Registry
- NCT00090298
Full record on ClinicalTrials.gov
From the registry
A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
Primary outcomes
- LDL-C lowering efficacy after 6 weeks.
History
Last registry update
Primary completion
Registered
Started